KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Common Equity (2017 - 2025)

Aquestive Therapeutics has reported Common Equity over the past 9 years, most recently at -$33.7 million for Q4 2025.

  • Quarterly results put Common Equity at -$33.7 million for Q4 2025, up 44.04% from a year ago — trailing twelve months through Dec 2025 was -$33.7 million (up 44.04% YoY), and the annual figure for FY2025 was -$33.7 million, up 44.04%.
  • Common Equity for Q4 2025 was -$33.7 million at Aquestive Therapeutics, down from -$4.1 million in the prior quarter.
  • Over the last five years, Common Equity for AQST hit a ceiling of -$4.1 million in Q3 2025 and a floor of -$118.6 million in Q4 2022.
  • Median Common Equity over the past 5 years was -$66.8 million (2025), compared with a mean of -$71.9 million.
  • Biggest five-year swings in Common Equity: tumbled 151.4% in 2021 and later surged 90.95% in 2025.
  • Aquestive Therapeutics' Common Equity stood at -$82.1 million in 2021, then crashed by 44.34% to -$118.6 million in 2022, then grew by 10.18% to -$106.5 million in 2023, then skyrocketed by 43.51% to -$60.2 million in 2024, then soared by 44.04% to -$33.7 million in 2025.
  • The last three reported values for Common Equity were -$33.7 million (Q4 2025), -$4.1 million (Q3 2025), and -$72.6 million (Q2 2025) per Business Quant data.